Omeros Corp (OMER) valuation
Omeros P/E ratio history
Omeros trades at 10.7 times its earnings over the last twelve months.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $17.18 | -$0.05 | n/m |
| Dec 31, 2024 | $9.88 | -$2.70 | n/m |
| Dec 31, 2023 | $3.27 | -$1.88 | n/m |
| Dec 31, 2022 | $2.26 | $0.76 | 3.0 |
| Dec 31, 2021 | $6.43 | $3.12 | 2.1 |
| Dec 31, 2020 | $14.29 | -$2.40 | n/m |
| Dec 31, 2019 | $14.09 | -$1.71 | n/m |
| Dec 31, 2018 | $11.14 | -$2.61 | n/m |
| Dec 31, 2017 | $19.43 | -$1.17 | n/m |
| Dec 31, 2016 | $9.92 | -$1.66 | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Omeros valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| OmerosOMER | $1.33B | 10.7 | — | 34.8 |
| ConmedCNMD | $1.33B | 18.3 | 9.4 | 1.0 |
| Tandem Diabetes CareTNDM | $1.31B | — | — | 1.3 |
| Us Physical TherapyUSPH | $1.31B | — | 27.6 | 1.6 |
| Nutex HealthNUTX | $1.38B | 7.7 | 7.3 | 1.6 |
| AnaptysbioANAB | $1.41B | — | 10.8 | 5.9 |
| Agilon HealthAGL | $1.42B | — | 77.3 | 0.2 |
| Opko HealthOPK | $1.25B | — | — | 2.1 |
| Tyra BiosciencesTYRA | $1.25B | — | — | — |
| Peer median | 13.0 | 10.8 | 1.6 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: OMER financials · OMER returns
No forecast, no recommendation. This page describes Omeros Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.